The MET gene, known for its role in cancer cell growth and metastasis, has long been a focal point in non-small cell lung cancer (NSCLC) treatment. Overexpression of MET in NSCLC has been linked to significant anti-cancer effects when targeted, and such therapies are already in clinical use. Now, the Yonsei team suggests this approach could extend to other solid tumors, including colorectal and gastric cancers.
The researchers found that MET gene aberrations are present across various cancer types, and early diagnosis paired with targeted therapy could enhance treatment outcomes. The study also highlights ongoing research into combination therapies, integrating MET inhibitors with immune checkpoint inhibitors and antibody-drug conjugates (ADCs).
A key finding centers on MET-targeted therapy as a novel option for patients who develop resistance to EGFR inhibitors. When resistance to EGFR inhibitors emerges, MET gene overexpression often compensates, driving tumor growth. By simultaneously targeting MET, the researchers propose, anti-cancer efficacy can be sustained.
The study underscores the growing potential of precision oncology, where therapies are tailored to specific genetic alterations, offering hope for improved outcomes across a broader spectrum of cancers.
Lim Hye Jung, HEALTH IN NEWS TEAM
press@hinews.co.kr
